

10. Ghazi A, Erturk E, Joseph J V. Modifications to facilitate extraperitoneal robot-assisted radical prostatectomy post kidney transplant. *JSLS J Soc Laparoendosc Surg*. 2012; 16(2): 314–19.
11. Mladá J, Vacková P. Kontrastní látky s obsahem gadolinia a nefrogenní systémová fibróza. *Urol praxi*. 2011; 12(3): 189–90.
12. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. *Invest Radiol*. 2008; 43(2): 141–44.
13. Townsend RR, Cohen DL, Katholi R, et al. Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency. *Am J Kidney Dis*. 2000; 36(6): 1207–12.
14. Chadban SJ, Ahn C, Axelrod DA, et al. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. *Transplantation*. 2020; 104(4S1 Suppl. 1): S11–103.
15. Jurdi A Al, Gilligan H, Cohen-Bucay A. Delaying Kidney Transplantation in Patients With Prostate Cancer: Is It Warranted? *Kidney Med*. 2021; 3(6): 893–95.
16. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2021. ISBN 978-94-92671-13-4.
17. Abramowicz D, Cochat P, Claas F, et al. Guideline. *Nephrol Dial Transplant*. 2013; 28(suppl_2): ii1–71.
18. Al-Adra DP, Hammel L, Roberts J, et al. Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. *Am J Transplant*. 2021; 21(2): 460–74.
19. Hsieh TC, Xu W, Chiao JW. Growth regulation and cellular changes during differentiation of human prostatic cancer LNCaP cells as induced by T lymphocyte-conditioned medium. *Exp Cell Res*. 1995; 218(1): 137–43.
20. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. *Nature*. 1999; 397(6719): 530–34.
21. Pollard M. Enhancement of metastasis of prostate adenocarcinoma cells by immune-suppressive cyclosporine A. *Cancer Lett*. 1997; 111(1–2): 221–24.
22. Robson R, Cecka JM, Opelz G, et al. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. *Am J Transplant*. 2005; 5(12): 2954–60.
23. David KM, Morris JA, Steffen BJ, et al. Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. *Clin Transplant*. 2005; 19(2): 279–85.
24. Kleinclauss F, Gigante M, Neuzillet Y, et al. Prostate cancer in renal transplant recipients. *Nephrol Dial Transplant*. 2008; 23(7): 2374–80.
25. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. *Cancer Res*. 2005; 65(7): 2825–31.
26. Cao C, Subhawong T, Albert JM, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. *Cancer Res*. 2006; 66(20): 10040–47.
27. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. *Transplantation*. 2005; 80(7): 883–89.
28. Kauffman HM, Cherikh WS, McBride MA, et al. Post-transplant de novo malignancies in renal transplant recipients: the past and present. *Transpl Int*. 2006; 19(8): 607–20.
29. Sheil AG. Patterns of malignancies following renal transplantation. *Transplant Proc*. 1999; 31(1–2): 1263–65.
30. Schaeffer EM, Srinivas S, Adra N, et al. NCCN Clinical Practice Guidelines in Oncology Prostate Cancer. 2023; 21(10): 1067–1096
31. Polcari AJ, Allen JC, Nunez-Nateras R, et al. Multicenter Experience With Robot-assisted Radical Prostatectomy in Renal Transplant Recipients. *Urology*. 2012; 80(6): 1267–72.